Lenabasum Safe and May Be Effective in Diffuse Scleroderma Patients
Robert F. Spiera, MD, rheumatologist at HSS, is interviewed at the annual ACR conference by MedPage Today talking about the study that he presented on the safety and efficacy of lenabasum in diffuse scleroderma patients.
He explains how his team saw significant improvements in skin scores, and in the primary efficacy outcome measure, the CRISS (Combined Response Index in diffuse cutaneous Systemic Sclerosis), over the course of this study.
"Most patients achieved a CRISS of greater than 90 percent by one year, which was encouraging… both in regard to safety and efficacy."
Dr. Spiera notes that there will be a phase III in the future.
Watch the video interview at MedPageToday.com.